WEBINAR:
Recent Developments in PGx: Predictive Biomarker Identification & Relevance
Newly identified biomarkers, and evidence to support their potential pharmacogenomic relevance, can help address challenges involved with optimizing personalized drug therapy.
In this webinar, Dr. David Kisor from Manchester University will present the latest evidence supporting newly identified (predictive) biomarkers for pharmacogenomics as well as evaluating the relevance of certain existing biomarkers. He will introduce a new resource that will be available for comparing and contrasting Clinical Pharmacogenetic Implementation Consortium and U.S. Food and Drug Administration PGx data.
In addition, Dr. Kisor will provide an overview of his updated educational modules that discuss the study of genetic variations in terms of an individual’s response to drugs.
Following Dr. Kisor’s presentation, Glenn Sawyer from Agena Bioscience will provide a brief, high-level overview of the company’s PGx capabilities.
PRESENTED BY:
At Agena Bioscience, we are dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective platform, the MassARRAY System, provides the capability for targeted genetic assays that satisfy the rigorous demands of genomic testing laboratories.